Cart
sales@molnova.com
Edasalonexent
CAS No. 1204317-86-1
Edasalonexent( CAT-1004 | CAT1004 )
Catalog No. M10746 CAS No. 1204317-86-1
Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 267 | Get Quote |
|
| 50MG | 1224 | Get Quote |
|
| 100MG | 1674 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEdasalonexent
-
NoteResearch use only, not for human use.
-
Brief DescriptionEdasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
-
DescriptionEdasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA); significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retriever DMD model; Edasalonexent is hydrolyzed by FAAH to release salicylic acid and DHA intracellularly and to suppress activated NF-κB.Other Indication Phase 2 Clinical.
-
In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and that is designed to synergistically leverage the ability of both of these compounds to inhibit NF-κB. Edasalonexent significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retrieverduchenne muscular dystrophy (DMD) model.
-
In VivoThe treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury.
-
SynonymsCAT-1004 | CAT1004
-
PathwayApoptosis
-
TargetNF-κB
-
RecptorNF-κB
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1204317-86-1
-
Formula Weight490.688
-
Molecular FormulaC31H42N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 120 mg/mL (244.56 mM)
-
SMILESO=C(NCCNC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)C1=CC=CC=C1O
-
Chemical NameN-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Aurantiamide
Aurantiamide has anti-cancer anti-inflammatory and antinociceptive activities it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB JNK and p38 pathways.
-
Eurycomalactone
Eurycomalactone is a natural product isolated from Eurycoma longifolia Jack., acts as a potent NF-κB inhibitor( IC50 of 0.5 μM).?Eurycomalactone inhibits protein synthesis, depletes cyclin D1, but does not affect TNFα-induced degradation of IκBα or the phosphorylation of IKKα/β and IκBα.
-
NF-κB-IN-1
NF-κB-IN-1 is a potent NF-κB signaling pathway inhibitor. It is a 4-arylidene crucumin analogue. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation.
